ClinicalTrials.gg
Not yet recruitingNCT07601204Updated May 22, 2026

Treatment of Recurrent/Metastatic Head and Neck Cancer

A Phase 1/2 interventional study of TQB2922 Subcutaneous Injection in Recurrent/Metastatic Head and Neck Cancer, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Not yet recruiting at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Head and Neck Neoplasms with a site in China — 86 open to participants now, 96 under way, 12 of them phase 3. Head and Neck Neoplasms · China.

Planned enrollment
58th of 145
128 · median 85
Started
2026
with 30 others
Phase 1/2
14 of 173
9 open now
Primary completion
2029-02
later than 86 of 95 live
Registered
152nd of 173
by date

Among the 173 studies in Head and Neck Neoplasms with a site in China, this one is the 58th largest by planned enrollment of the 145 interventional ones that give a count, is one of 31 that started in 2026, is one of 14 in phase 1/2, reaches primary completion later than 86 of the 95 other live ones, and was the 152nd registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

86 of the 173 studies in Head and Neck Neoplasms with a site in China are open now. Recruiting first, the newest first:

81 more — sign in →

All 86 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Head and Neck Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous) administered once every 3 weeks in subjects with R/M HNC. The Phase II stage explored the efficacy and safety of TQB2922 (subcutaneous) as monotherapy or in combination therapy in subjects with R/M HNC.

03

Conditions studied

  • Recurrent/Metastatic Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject voluntarily enrolls in the study, signs the form, and has good compliance.
  • Aged 18 to 75 years inclusive (calculated on the date of informed consent signing).
  • (ECOG) performance status score of 0-1.
  • Expected survival > 12 weeks.
  • Subjects with or cytologically confirmed recurrent/ head and neck cancer (R/M HNC) and no indication for curative local therapy.head and neck cancer (HNC)
  • At least one per 1.1 criteria. If the target lesion is within the prior radiotherapy field, the lesion must be confirmed as progressive disease.
  • Adequate major organ function, meeting the following laboratory criteria (no blood transfusion within 14 days prior to screening; no hematopoietic growth factors or other corrective medications administered within 7 days prior to screening):

    • (HGB) ≥ 90 g/L;
    • (NEUT) ≥ 1.5×10⁹/L;
    • count (PLT) ≥ 100×10⁹/L;
    • Total (TBIL) ≤ 1.5× (ULN); ≤ 2.0×ULN in subjects with liver metastasis;
    • (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; ≤ 5.0×ULN in subjects with liver metastasis;
    • (CCR) ≥ 50 mL/min (calculated using the standard Cockcroft-Gault formula). For subjects not receiving platinum-containing chemotherapy, serum creatinine (Cr) ≤ 1.3×ULN is also acceptable.
    • Serum albumin ≥ 30 g/L;
    • (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5×ULN (in subjects not receiving anticoagulant therapy).
  • Echocardiographic assessment: (LVEF) ≥ 50%.
  • Females of agree to use effective during the study and for 6 months after study completion; serum or urine pregnancy test must be negative within 7 days prior to enrollment. Males agree to use effective contraception during the study and for 6 months after study completion (see Section 5.5 for details).

Additional criteria for Expansion Cohort 1 and Cohort 2:

  • Has received at least one for recurrent/metastatic disease, including platinum-based chemotherapy and anti-programmed cell death protein 1 / programmed cell death ligand 1 (/L1) therapy.

Systemic therapy administered as part of multimodal treatment for locally advanced disease (including /induction, concurrent, adjuvant/consolidation therapy), with disease recurrence or progression during chemotherapy/immunotherapy or within 6 months after the last dose, shall be defined as first-line chemotherapy/immunotherapy failure.

  • No prior exposure to paclitaxel and its novel formulations (e.g., albumin-bound paclitaxel) (Cohort 2 only).

Additional criteria for Expansion Cohort 3

  • No prior systemic therapy for recurrent/metastatic disease. Systemic therapy as part of multimodal treatment for locally advanced disease (including induction/neoadjuvant therapy, concurrent systemic therapy with curative radiotherapy, adjuvant/consolidation therapy) is excluded, provided that the interval from completion of such therapy to disease recurrence/progression exceeds 6 months.

Exclusion criteria

Exclusion Criteria:

  • Current or history of other malignant tumors. The following two conditions are allowed for enrollment:

Other malignant tumors treated with surgery alone with continuous 5-year disease-free survival (DFS); cured carcinoma in situ of cervix, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invading basement membrane)].

  • Diseases that interfere with subcutaneous injection or venous blood collection.
  • Adverse reactions from prior treatment have not recovered to ≤Grade 1 per Version 6.0, except Grade 2 alopecia, Grade 2 peripheral neurotoxicity (Cohort 1 only), Grade 2 anemia, non- asymptomatic Grade 2 laboratory abnormalities, hypothyroidism stabilized by hormone replacement therapy, and other toxicities deemed to have no safety risk by the investigator.
  • Major surgical treatment, significant traumatic injury within 4 weeks prior to the first dose, or planned major surgery during the study treatment period (excluding protocol-specified surgeries); or unhealed wounds or fractures for a long time.

Major surgery is defined as Grade 3 or above surgeries in the 2022 National Surgery Classification Catalogue.

  • Any bleeding event ≥Grade 3 per CTCAE within 4 weeks prior to the first dose.
  • Arterial/venous thromboembolic events within 6 months prior to the first dose, including cerebrovascular accidents (including , excluding lacunar cerebral infarction). Implantable venous port/catheter-related thrombosis or superficial venous thrombosis shall not be regarded as "severe" thromboembolism); deep venous thrombosis and pulmonary embolism.
  • Active and poorly controlled viral hepatitis. Subjects meeting the following criteria may undergo screening:

-positive subjects must have Hepatitis B Virus Deoxyribonucleic Acid (HBV) DNA \<500 IU/mL (or 2500 copies/mL), and agree to receive anti-HBV therapy throughout the study.

-infected subjects (HCV Ab or HCV RNA positive): HCV viral RNA ≤, and continue approved antiviral therapy during the study.

  • Active syphilis requiring treatment.
  • Active pulmonary tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia/radiation pneumonitis requiring treatment, active pneumonia with obvious clinical symptoms; history of interstitial lung disease (ILD) requiring previous treatment, or current interstitial lung disease.
  • History of psychoactive substance abuse without abstinence, or mental disorders.
  • Planned or prior bone marrow transplantation or solid organ transplantation.
  • History of hepatic encephalopathy.
  • Severe cardiovascular diseases, including any of the following:

    • Cardiac insufficiency ≥ (NYHA) Class II, or echocardiography showing (LVEF) \<50%.
    • History of clinically significant ventricular arrhythmia (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes), or arrhythmia requiring continuous antiarrhythmic medication. Subjects with stable atrial fibrillation controlled by β-blockers alone may be enrolled after investigator's assessment.
    • Unstable angina pectoris.
    • Myocardial infarction within 12 months. Subjects who received interventional treatment more than 6 months ago without sequelae may be enrolled.
    • interval (QTc): >450 ms in males, >470 ms in females. If QTc is abnormal, three consecutive measurements at an interval >2 minutes shall be performed and the average value adopted. Correction methods include Fridericia formula or Bazett formula.
    • History or family history of congenital long QT syndrome.
  • Active or uncontrolled severe infection (≥CTCAE Grade 2 infection).
  • Renal failure requiring hemodialysis or peritoneal dialysis.
  • History of immunodeficiency, including positivity, or other acquired/congenital immunodeficiency diseases.
  • Uncontrolled diseases requiring agents or systemic for immunosuppressive purposes, and still requiring such treatment within 7 days prior to the first dose.

Exclusion does not apply to subjects receiving prednisone \<10 mg daily or equivalent dose of other corticosteroids.

  • Epilepsy requiring treatment.
  • Poorly controlled diabetes [fasting blood glucose (FBG)>10 mmol/L].
  • Tumor-related conditions and prior therapies:

    • Received chemotherapy, immunotherapy, small-molecule targeted therapy within 3 weeks prior to the first dose, or still within 5 half-lives of the drug (whichever is longer). The is calculated from the date of the last treatment.

Prior local radiotherapy is allowed if: radiotherapy completed >4 weeks prior to study treatment initiation (>2 weeks for brain radiotherapy); target lesion selected in this study is outside the radiotherapy field; or target lesion within radiotherapy field with confirmed progression.

  • Received proprietary Chinese medicines with anti-tumor indications specified in National Medical Products Administration approved drug instructions within 1 week prior to the first dose (including Compound Mylabris Capsule, Kang'ai Injection, Kanglaite Capsule/Injection, Aidi Injection, Brucea Javanica Oil Injection/Capsule, Xiaoaiping Tablets/Injection, Huachansu Capsule, etc.).
  • Imaging (CT/MRI) shows tumor invasion of major blood vessels, or the investigator judges that the tumor is highly likely to invade major blood vessels and cause fatal massive hemorrhage during subsequent study treatment.
  • Uncontrolled recurrent pleural effusion, pericardial effusion or moderate to severe ascites requiring repeated drainage (as assessed by investigator).
  • Known spinal cord compression, meningeal /carcinomatous meningitis, with symptoms, or brain metastasis with symptomatic/radiographic control duration \<4 weeks; still requiring steroids or dehydrating agents within 2 weeks prior to study treatment initiation.

Subjects with newly diagnosed or progressive brain metastasis at screening shall be re-examined after at least 4 weeks to confirm stability.

  • Known to study drug or .
  • Received more than 2 for recurrent/metastatic disease (Cohort 1 and Cohort 2).
  • Prior treatment with EGFR-targeted antibodies/Antibody-Drug Conjugates (ADCs). Exclusion does not apply to subjects who received cetuximab or nimotuzumab during curative radiotherapy for locally advanced disease, with disease recurrence/progression occurring >6 months after completion of curative radiotherapy and the last dose.
  • Prior treatment with more than one , or prior Transforming Growth Factor Beta targeted therapy (Cohort 3).
  • Participated in another anti-tumor clinical trial and received drugs within 4 weeks prior to the first dose.
  • Conditions judged by the investigator to pose serious risks to subject safety or impair completion of the study.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    TQB2922 Subcutaneous Injection

    TQB2922 subcutaneous injection: During the first cycle, it is administered once a week, and subsequently it is administered once every three weeks, with one dose given in the morning.

    Drug: TQB2922 Subcutaneous Injection

Interventions

  • TQB2922 injection is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/Hepatocyte Growth Factor Receptor (c-Met).

06

What researchers measure

Primary outcomes

  1. Recommended Dose for Phase II (RP2D)

    Recommended Dose for Phase II (RP2D)

    Time frame: Through study completion, an average of 1 year

  2. Time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax)

    Time frame: 0.5 hour before dosing, 4, 10, 24, 48, 72 hours after dosing on cycle 1 day 1, 0.5 hour before dosing on cycle 1 day 8, 0.5 hour before dosing on cycle 1 day 15, (each cycle is 21 days)

  3. Maximum concentration (Cmax)

    Maximum concentration (Cmax)

    Time frame: 0.5 hour before dosing, 4, 10, 24, 48, 72 hours after dosing on cycle 1 day 1, 0.5 hour before dosing on cycle 1 day 8, 0.5 hour before dosing on cycle 1 day 15, (each cycle is 21 days)

  4. Area under the concentration-time curve from time 0 to time t (AUC0-t)

    Area under the concentration-time curve from time 0 to time t (AUC0-t)

    Time frame: 0.5 hour before dosing, 4, 10, 24, 48, 72 hours after dosing on cycle 1 day 1, 0.5 hour before dosing on cycle 1 day 8, 0.5 hour before dosing on cycle 1 day 15, (each cycle is 21 days)

  5. Elimination half-life (t1/2)

    Elimination half-life (t1/2)

    Time frame: 0.5 hour before dosing, 4, 10, 24, 48, 72 hours after dosing on cycle 1 day 1, 0.5 hour before dosing on cycle 1 day 8, 0.5 hour before dosing on cycle 1 day 15, (each cycle is 21 days)

  6. Clearance (CL)

    Clearance (CL)

    Time frame: 0.5 hour before dosing, 4, 10, 24, 48, 72 hours after dosing on cycle 1 day 1, 0.5 hour before dosing on cycle 1 day 8, 0.5 hour before dosing on cycle 1 day 15, (each cycle is 21 days)

  7. Ctrough

    Ctrough

    Time frame: 0.5 hour before dosing, 4, 10, 24, 48, 72 hours after dosing on cycle 1 day 1, 0.5 hour before dosing on cycle 1 day 8, 0.5 hour before dosing on cycle 1 day 15, (each cycle is 21 days)

Secondary outcomes

  1. Overall response rate (ORR)

    After enrollment of all patients, the proportion of participants with the best overall efficacy rated as complete response or partial response according to criteria (RECIST1.1).

    Time frame: The estimated duration was 16 months from enrollment of the first patient to 10 months after enrollment of the last patient.

  2. Duration of response (DOR)

    Patient from the date of first documentation of objective remission of the tumor to the date of first documentation of objective progression of the tumor or the date of death due to any cause.

    Time frame: The estimated duration was 16 months from enrollment of the first patient to 10 months after enrollment of the last patient.

  3. Disease control rate (DCR)

    Proportion of participants with complete response, partial response, and stable disease as rated by RECIST v1.1 criteria for best overall efficacy after enrollment of all patients.

    Time frame: The estimated duration was 16 months from enrollment of the first patient to 10 months after enrollment of the last patient.

  4. Overall survival (OS)

    The time from randomization to death due to any cause.

    Time frame: From randomization until patient death, it is expected to be evaluated up to 5 years.

  5. Number of patients with adverse events (AEs) and serious adverse events (SAEs)

    Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Baseline up to 90 days after the last dose

  6. Severity of AE/SAE

    Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Baseline up to 90 days after the last dose

  7. Immunogenicity indicators: anti-drug antibodies (ADA)

    Usually refers specifically to antidrug-binding antibodies.

    Time frame: Day 1 of cycles 1, 2, 4, 6, and 8 (within 30 minutes before administration, end of treatment follow-up (EOT), 90 days after the last administration).

07

Study locations

10 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Feb 2029, 32 months later.

Of 51 industry-sponsored phase 1/2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 32 months is below that.

Counting every sponsor, half of 90 studies reached it within 54 months; a quarter within 41 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2026
First posted
May 22, 2026
StartEst.
Jun 2026
Primary completionEst.
Feb 2029
CompletionEst.
Dec 2030
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07601204
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 2026 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 22, 2026

Study contacts

Kunyu Yang, Doctor
Contact
Yangky71@aliyun.com
13995595360

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB2922

Start the discussion